ARSENALBIO
ARSENALBIO logo

Arsenal Biosciences, Inc. is a privately held programmable cell therapy company discovering and developing a pipeline of next-generation autologous T cell therapies to defeat cancer. ArsenalBio's full-stack R&D engine generates multifunctional T cell medicines, enabled by precise and specific CRISPR-mediated insertion of large synthetic DNA cassettes. ArsenalBio is building the industry’s largest DNA library of therapeutic enhancing integrated circuits, incorporating logic gating for improved tumor targeting and synthetic features enabling multiple pharmaceutical functions. In pioneering a computationally driven approach alongside nonviral clinical manufacturing, ArsenalBio aspire to deliver enhanced efficacy, increased patient safety, reduced stakeholder costs, and expanded market access.

Disclaimer : All logos and trademarks on this website are the property of their respective owners. The information on this website is not a medical or investment related advice. The information about the company might not reflect the most current or accurate information. Please refer to the company's respective website for the most accurate information.

© 2023-24 DxMultiomics. All rights reserved.